Drug Drug Interactions with VICTRELIS® (boceprevir) Informative ...
Drug Drug Interactions with VICTRELIS® (boceprevir) Informative ...
Drug Drug Interactions with VICTRELIS® (boceprevir) Informative ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Class of<br />
<strong>Drug</strong><br />
16<br />
BETA BLOCKERS<br />
Substrate<br />
class<br />
<strong>Drug</strong> Brand name (non<br />
exhaustive list,<br />
generics not listed).<br />
For a complete list,<br />
please consult<br />
www.bcfi.be or<br />
www.cbip.be<br />
Atenolol Tenormine ® ,<br />
Tenoretic ® , Tenif ®<br />
Bisoprolol Emconcor ® , Isoten ® ,<br />
Emcoretic ® , Lodoz ® ,<br />
Maxsoten ®<br />
Liverpool University (*) /<br />
Extra-information<br />
Not Clinically<br />
Significant<br />
No information<br />
available<br />
Carvedilol No information<br />
available<br />
Nebivolol Tyskiten ® , Nobiten ® ,<br />
Hypoloc ® , Nobiretic ®<br />
Potential<br />
Interaction<br />
Esmolol Brevibloc ® No information<br />
available<br />
Metoprolol Seloken ® , Lopresor ® ,<br />
Selozok ® , Logroton<br />
Divitabs ® , Zok-Zid ® ,<br />
Logimat ®<br />
Potential<br />
Interaction<br />
Pindolol Visken ® , Viskaldix ® No information<br />
available<br />
Propanolol Inderal ® Not Clinically<br />
Significant<br />
Recommendations SmPC/<br />
Scientific Literature<br />
Dose reductions could<br />
be considered for<br />
carvedilol in patients<br />
initiating BOCk Dose reductions could<br />
be considered for<br />
nebivolol in patients<br />
initiating BOCk .<br />
Nebivolol UE SmPC:<br />
contraindication in<br />
patients <strong>with</strong> hepatic<br />
insufficiency or impaired<br />
liver function*<br />
In patients <strong>with</strong> severe<br />
hepatic dysfunction,<br />
a reduction in dosage<br />
may be necessary*<br />
Kiser et al., hepatology 2012:<br />
dose reductions could be<br />
considered for carvedilol and<br />
nebivolol in patients initiating<br />
BOC k<br />
CYP pathway(s)<br />
(www.cbip/bcfi.be)<br />
(www.mims.com.au)<br />
CYP2C9 / CYP 2D6<br />
CYP2D6<br />
CYP2D6<br />
CYP2D6<br />
CYP1A2 / CYP2C19 /<br />
CYP2D6 / CYP3A4<br />
CYP3A4<br />
Substrate/<br />
Inhibitor/<br />
Inducer<br />
Substrate
Change language